2021
DOI: 10.1016/j.ymthe.2020.11.021
|View full text |Cite
|
Sign up to set email alerts
|

PDE10A Inhibition Reduces the Manifestation of Pathology in DMD Zebrafish and Represses the Genetic Modifier PITPNA

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(2 citation statements)
references
References 94 publications
0
2
0
Order By: Relevance
“…In this study, 23 molecules were selected for a nutraceutical screening either on the basis of their role as phosphodiesterase inhibitors, which have a known anti-inflammatory action on muscle, or because they are antioxidants known to counteract enhanced free radical production [30]. Mortality, improved locomotion, and a reduced number of larvae with impaired birefringence were taken as efficacy endpoints [31].…”
Section: Discussionmentioning
confidence: 99%
“…In this study, 23 molecules were selected for a nutraceutical screening either on the basis of their role as phosphodiesterase inhibitors, which have a known anti-inflammatory action on muscle, or because they are antioxidants known to counteract enhanced free radical production [30]. Mortality, improved locomotion, and a reduced number of larvae with impaired birefringence were taken as efficacy endpoints [31].…”
Section: Discussionmentioning
confidence: 99%
“…Using the zebrafish dystrophin-deficient model, an inhibitor of the phosphodiesterase 10A (PDE10A) was found to reduce the manifestation of the dystrophic muscle phenotype. Moreover, PDE10A inhibition in zebrafish and in DMD patient-derived myoblasts were also associated with reduction of PITPα expression [ 99 ]. Thus, these results indicate a reduction in PITPα as a protective genetic modifier in dystrophin-deficient model systems and permits the escape of the dystrophic phenotype.…”
Section: Class I Pitpsmentioning
confidence: 99%